Who is sponsoring NCT03347474?

NCT03347474 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT03347474?

Interventions in NCT03347474: Bilateral surgical implantation of DBS system to NAc.

What condition does NCT03347474 study?

NCT03347474 studies Treatment Methamphetamine Addiction.

Is NCT03347474 still recruiting?

NCT03347474 is currently status unknown. Last updated 26 October 2018.

Last reviewed 2018-10-26 · How we verify

NCT03347474

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep Brain Stimulation of Nucleus Accumbens for Methamphetamine Addiction

Status unknown NA Last updated 26 October 2018

What this trial tests

NA trial testing Bilateral surgical implantation of DBS system to NAc in Treatment Methamphetamine Addiction in 10 participants. Status unknown.

Timeline

20 September 2017

Primary endpoint
20 September 2020

30 December 2020

Quick facts

Lead sponsor	Ruijin Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	20 September 2017
Primary completion	20 September 2020
Estimated completion	30 December 2020
Sites	1 location across China

Drugs / interventions tested

Bilateral surgical implantation of DBS system to NAc

Conditions studied

Treatment Methamphetamine Addiction — all drugs for Treatment Methamphetamine Addiction →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 65, any sex, with Treatment Methamphetamine Addiction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to assess the efficacy of bilateral deep brain stimulation (DBS) of the Nucleus Accumbens(NAc) as a novel treatment in severe methamphetamine addiction. Our hypothesis is that bilateral DBS of the NAc will significantly reduce the craving for methamphetamine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
Rissardo JP, Vora NM, Tariq I, Mujtaba A, et al · · 2023 · cited 17× · PMID 38004040 · DOI 10.3390/medicina59111991

Verify or expand the search:

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03347474 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 26 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03347474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing